BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 34330673)

  • 1. Primary Mediastinal B-Cell Lymphoma: A 2021 Update on Genetics, Diagnosis, and Novel Therapeutics.
    Ahmed Z; Afridi SS; Shahid Z; Zamani Z; Rehman S; Aiman W; Khan M; Mir MA; Awan FT; Anwer F; Iftikhar R
    Clin Lymphoma Myeloma Leuk; 2021 Nov; 21(11):e865-e875. PubMed ID: 34330673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary Mediastinal B-Cell Lymphoma in Children and Young Adults.
    Forlenza CJ; Chadburn A; Giulino-Roth L
    J Natl Compr Canc Netw; 2023 Mar; 21(3):323-330. PubMed ID: 36898366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current and emerging treatment options in primary mediastinal B-cell lymphoma.
    Fakhri B; Ai W
    Ther Adv Hematol; 2021; 12():20406207211048959. PubMed ID: 34659697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary mediastinal large B-cell lymphoma.
    Savage KJ
    Blood; 2022 Sep; 140(9):955-970. PubMed ID: 34496020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic factors, therapeutic approaches, and distinct immunobiologic features in patients with primary mediastinal large B-cell lymphoma on long-term follow-up.
    Zhou H; Xu-Monette ZY; Xiao L; Strati P; Hagemeister FB; He Y; Chen H; Li Y; Manyam GC; Li Y; Montes-Moreno S; Piris MA; Young KH
    Blood Cancer J; 2020 May; 10(5):49. PubMed ID: 32366834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary Mediastinal (Thymic) Large B-Cell Lymphoma: Fidelity of Diagnosis Using WHO Criteria.
    Fairchild A; McCall CM; Oyekunle T; Niedzwiecki D; Champ C; McKinney M; Kelsey CR
    Clin Lymphoma Myeloma Leuk; 2021 May; 21(5):e464-e469. PubMed ID: 33487576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of pembrolizumab in relapsed/refractory primary mediastinal large B-cell lymphoma.
    Tomassetti S; Chen R; Dandapani S
    Ther Adv Hematol; 2019; 10():2040620719841591. PubMed ID: 31040936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ruxolitinib shows activity against Hodgkin lymphoma but not primary mediastinal large B-cell lymphoma.
    Kim SJ; Yoon DH; Kang HJ; Hong JY; Lee HS; Oh SY; Shin HJ; Kong JH; Yi JH; Sakamoto K; Ko YH; Huh J; Lee SS; Takeuchi K; Shin DY; Suh C; Kim WS
    BMC Cancer; 2019 Nov; 19(1):1080. PubMed ID: 31707975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Progress in treatment of primary mediastinal large B-cell lymphoma].
    Chen LW; Li JY; Fan L
    Zhonghua Xue Ye Xue Za Zhi; 2024 Jan; 45(1):98-102. PubMed ID: 38527847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biology and therapy of primary mediastinal B-cell lymphoma: current status and future directions.
    Lees C; Keane C; Gandhi MK; Gunawardana J
    Br J Haematol; 2019 Apr; 185(1):25-41. PubMed ID: 30740662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real world experience of R-CHOP with or without consolidative radiotherapy vs DA-EPOCH-R in the first-line treatment of primary mediastinal B-cell lymphoma.
    Chan EHL; Koh LP; Lee J; De Mel S; Jeyasekharan A; Liu X; Tang T; Lim ST; Tao M; Quek R; Farid Bin Harunal Ras M; Lee YS; Diong C; Tan D; Kim SJ; Chee YL; Poon LMM
    Cancer Med; 2019 Aug; 8(10):4626-4632. PubMed ID: 31264808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary mediastinal lymphoma: diagnosis and treatment options.
    Martelli M; Di Rocco A; Russo E; Perrone S; Foà R
    Expert Rev Hematol; 2015 Apr; 8(2):173-86. PubMed ID: 25537750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience.
    Savage KJ; Al-Rajhi N; Voss N; Paltiel C; Klasa R; Gascoyne RD; Connors JM
    Ann Oncol; 2006 Jan; 17(1):123-30. PubMed ID: 16236753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hitting back at lymphoma: How do modern diagnostics identify high-risk diffuse large B-cell lymphoma subsets and alter treatment?
    Abramson JS
    Cancer; 2019 Sep; 125(18):3111-3120. PubMed ID: 31287161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma: a multi-centre analysis.
    Shah NN; Szabo A; Huntington SF; Epperla N; Reddy N; Ganguly S; Vose J; Obiozor C; Faruqi F; Kovach AE; Costa LJ; Xavier AC; Okal R; Kanate AS; Ghosh N; Kharfan-Dabaja MA; Strelec L; Hamadani M; Fenske TS; Calzada O; Cohen JB; Chavez J; Svoboda J
    Br J Haematol; 2018 Feb; 180(4):534-544. PubMed ID: 29265182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The molecular pathogenesis of primary mediastinal large B-cell lymphoma.
    Steidl C; Gascoyne RD
    Blood; 2011 Sep; 118(10):2659-69. PubMed ID: 21700770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH-R.
    Giulino-Roth L; O'Donohue T; Chen Z; Bartlett NL; LaCasce A; Martin-Doyle W; Barth MJ; Davies K; Blum KA; Christian B; Casulo C; Smith SM; Godfrey J; Termuhlen A; Oberley MJ; Alexander S; Weitzman S; Appel B; Mizukawa B; Svoboda J; Afify Z; Pauly M; Dave H; Gardner R; Stephens DM; Zeitler WA; Forlenza C; Levine J; Williams ME; Sima JL; Bollard CM; Leonard JP
    Br J Haematol; 2017 Dec; 179(5):739-747. PubMed ID: 29082519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical Characteristics and Prognosis of 56 Lymphoma Patients with Mediastinal Masses].
    Yu H; Wang L; Zhu HY; Wu W; Liang JH; Yin H; Fan L; Li JY; Xu W
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Apr; 28(2):495-499. PubMed ID: 32319385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relapsed/refractory primary mediastinal large B-cell lymphoma: a structured review of epidemiology, treatment guidelines and real-world treatment practices.
    Takyar J; Raut M; Borse R; Balakumaran A; Sehgal M
    Expert Rev Hematol; 2020 Mar; 13(3):275-287. PubMed ID: 31951774
    [No Abstract]   [Full Text] [Related]  

  • 20. DLBCL with amplification of JAK2/PD-L2 exhibits PMBCL-like CNA pattern and worse clinical outcome resembling those with MYD88 L265P mutation.
    Xue X; Huang W; Qiu T; Guo L; Ying J; Lv N
    BMC Cancer; 2020 Aug; 20(1):816. PubMed ID: 32854650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.